OTCMKTS:ASPCF Acerus Pharmaceuticals (ASPCF) Stock Price, News & Analysis $0.22 0.00 (0.00%) As of 07/21/2023 Add Compare Share Share Stock Analysis Stock Analysis About Acerus Pharmaceuticals Stock (OTCMKTS:ASPCF) Get Acerus Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.22▼$0.2250-Day Range$0.22▼$0.2252-Week Range$0.22▼$8.16VolumeN/AAverage Volume1,500 shsMarket Capitalization$1.70 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Acerus Pharmaceuticals Corporation was a Canadian specialty pharmaceutical company focused primarily on developing and commercializing treatments for men’s health. The company’s leading product was NATESTO, a testosterone nasal gel prescribed for testosterone replacement therapy in adult men with conditions associated with testosterone deficiency. NATESTO was developed as an alternative to injectable, transdermal and other testosterone replacement products. Acerus pursued regulatory approvals and commercial distribution in North America and worked with licensing and distribution partners to expand access to its products. The company was formerly known as Trimel Pharmaceuticals Corporation and adopted the Acerus name as it broadened its specialty pharmaceutical strategy. Acerus was based in Canada and served markets including Canada and the United States. The company subsequently encountered financial and operational difficulties and entered creditor-protection proceedings, after which its business and product operations were subject to restructuring and asset-sale activity. Information about its current corporate operations and leadership is limited.AI Generated. May Contain Errors. Read More Receive ASPCF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ASPCF Stock News HeadlinesAcerus Announces Commencement of Court-Approved Sale and Investment Solicitation ProcessMarch 14, 2023 | finance.yahoo.comAcerus Pharmaceuticals: Top 10 Undervalued Nano Cap Stocks on TSX (ASP)January 16, 2023 | theglobeandmail.comTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered. Buried inside is what some call the legal groundwork for the biggest change to American money in over a century, with a key Treasury vote potentially as soon as January 18. Ian King, Chief Strategist at Strategic Fortunes, breaks down what the order could mean for the dollar and the financial system.October 16 at 1:00 AM | Banyan Hill Publishing (Ad)Acerus Reports Third Quarter 2022 Financial ResultsNovember 15, 2022 | finance.yahoo.comAcerus Announces Amendment to Promissory Note Due to Former Serenity ShareholdersOctober 3, 2022 | finance.yahoo.comAcerus Pharmaceuticals to Initiate Strategic Review of OperationsSeptember 21, 2022 | marketwatch.comAcerus Announces Initiation of Strategic ReviewSeptember 21, 2022 | finance.yahoo.comAcerus Pharmaceuticals CFO resigns effective November 20, 2022August 23, 2022 | seekingalpha.comSee More Headlines ASPCF Stock Analysis - Frequently Asked Questions How have ASPCF shares performed this year? Acerus Pharmaceuticals' stock was trading at $0.22 at the beginning of 2026. Since then, ASPCF stock has increased by 0.0% and is now trading at $0.22. When did Acerus Pharmaceuticals' stock split? Acerus Pharmaceuticals's stock reverse split on the morning of Friday, April 29th 2022.The 1-200 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. Company Calendar Today10/16/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:ASPCF CIKN/A Webwww.aceruspharma.com Phone(416) 679-0771Fax905-569-1809Employees14Year Founded2008Profitability EPS (Trailing Twelve Months)($3.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$33.82 million Net Margins-924.33% Pretax Margin-924.33% Return on EquityN/A Return on Assets-74.62% Debt Debt-to-Equity RatioN/A Current Ratio0.67 Quick Ratio0.34 Sales & Book Value Annual Sales$2.12 million Price / Sales0.80 Cash FlowN/A Price / Cash FlowN/A Book Value($3.38) per share Price / Book-0.07Miscellaneous Outstanding Shares7,708,000Free FloatN/AMarket Cap$1.70 million OptionableNot Optionable Beta0.69 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (OTCMKTS:ASPCF) was last updated on 7/21/2023 by MarketBeat.com Staff. From Our PartnersElon Musk’s 4th Wealth Window Set to Open by October 30Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredSpaceX minted 4400 millionaires in a single daySpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into milliona...Behind the Markets | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acerus Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acerus Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
